Legal Opinion
In Re Fosamax (Alendronate Sodium) Products Liability Litigation
Court of Appeals for the Third Circuit
Decided March 22, 2017No. 14-1900 et alPublishedCited by 34 opinions
1Opinion of the Court
OPINION OF THE COURT
FUENTES, Circuit Judge.
Beginning in 2010, hundreds of plaintiffs filed personal-injury suits against the drug manufacturer Merck Sharp & Dohme, alleging that the osteoporosis drug Fosamax caused them to suffer serious thigh bone fractures. Each Plaintiff brought a state-law tort claim alleging that Merck failed to add an adequate warning of the risk of thigh fractures to Fosamax’s FDA-approved drug label. Many Plaintiffs also brought a variety of additional claims including defective design, negligence, and breach of warranty.
Plaintiffs’ suits were consolidated for…
2Cases cited43 opinions
- Anderson v. Liberty Lobby, Inc.Supreme Court of the United States · 1986
- MARKMAN Et Al. v. WESTVIEW INSTRUMENTS, INC., Et Al.Supreme Court of the United States · 1996
- Gibbons v. OgdenSupreme Court of the United States · 1824
- Pullman-Standard v. SwintSupreme Court of the United States · 1982
- United States v. ArmstrongSupreme Court of the United States · 1996
38 more not listed; retrieve them via the Exa API.
3Cited by34 opinions
- Gibbons v. Bristol-Myers Squibb Co.Court of Appeals for the Second Circuit · 2019
- Walter Shuker v. Smith & Nephew PLCCourt of Appeals for the Third Circuit · 2018
- Leonard Cottrell v. Alcon LaboratoriesCourt of Appeals for the Third Circuit · 2017
- Merck Sharp & Dohme Corp. v. AlbrechtSupreme Court of the United States · 2019
- In Re Wellbutrin XL Antitrust Litigation Indirect Purchaser ClassCourt of Appeals for the Third Circuit · 2017
29 more not listed; retrieve them via the Exa API.